VivoSeq
Oncology

Giant Cell Tumor

14

Pipeline Programs↗

9

Active Trials↗

10

Companies Involved↗

Giant Cell Tumor is an emerging landscape with 14 programs across 10 companies. The most active players are Deciphera Pharmaceuticals, LLC, Five Prime Therapeutics, Inc., Azurity Pharmaceuticals. 2 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

75/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

D

Deciphera Pharmaceuticals, LLC

1 program

Phase 2F

Five Prime Therapeutics, Inc.

1 program

Phase 2A

Azurity Pharmaceuticals

1 program

Phase 2Daiichi Sankyo logo

Daiichi Sankyo

2 programs

Phase 2A

Abbisko Therapeutics Co, Ltd

1 program

Phase 3Pfizer logo

Pfizer

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

77%

Small molecule

10 of 13 classified programs — the dominant modality here.

23%ALL OTHERSMonoclonal antibody215%Protein / enzyme18%

Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 100% of 15 pipeline programs.

Analysis

Trial Status

23

clinical trials

Completed9 · 39%
Active, not recruiting4 · 17%
Recruiting4 · 17%
Terminated3 · 13%
Unknown status2 · 9%
Not yet recruiting1 · 4%

Clinical Trials

Trial Activity

23 trials

Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Giant Cell Tumor of Bone Surgery
Recruiting·SShanghai Jiao Tong University Affiliated Sixth People's Hospital·Phase 4·NCT07315828·40 enrolled
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
Recruiting·SSt. Louis University·Phase 3·NCT03295981·120 enrolled
Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study
Recruiting·—·Phase 1/2·NCT06647901·45 enrolled
Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor Surgery
Recruiting·SShanghai Jiao Tong University Affiliated Sixth People's Hospital·Phase 4·NCT07315841·40 enrolled
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
Active, not recruiting·SSynOx Therapeutics Limited·Phase 3·NCT05417789·128 enrolled
Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
Active, not recruiting·Amgen logoAmgen·Phase 4·NCT04586660·36 enrolled
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
Active, not recruiting·DDeciphera Pharmaceuticals, LLC·Phase 3·NCT05059262·123 enrolled
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
Active, not recruiting·AAbbisko Therapeutics Co, Ltd·Phase 3·NCT05804045·90 enrolled
A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone
Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT05813665·146 enrolled
Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone
Completed·Amgen logoAmgen·Phase 2·NCT00396279·37 enrolled
A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone
Completed·SShanghai JMT-Bio Inc.·N/A·NCT05402865·301 enrolled
Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
Completed·Amgen logoAmgen·Phase 4·NCT03301857·85 enrolled
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
Completed·Daiichi Sankyo logoDaiichi Sankyo·Phase 3·NCT02371369·120 enrolled
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
Completed·Amgen logoAmgen·Phase 2·NCT00680992·535 enrolled
An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
Completed·AAmMax Bio, Inc.·Phase 2·NCT04731675·11 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)